

PRESS RELEASE
Strides Arcolab receives ANDA approval for
Rifampicin for Injection USP, 600 mg / vial

Bangalore, India: May 23, 2008

Strides Arcolab today announced receipt of ANDA approval for Rifampicin for Injection USP, 600 mg / vial.

The product is licensed to Akorn-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akorn, Inc [NASDAQ: AKRX] and Strides Arcolab Limited [NSE: STAR, BSE: 532531]

Mr. Arun Kumar – Vice Chairman and Group CEO of Strides Arcolab stated:

“These approvals reflect yet another significant milestone for the Akorn-Strides partnership which now has approvals for seven sterile injectable products and plans for commercialization are underway.”

About Strides Arcolab Limited

Strides, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is one of India's largest exporters of branded generic pharmaceutical products. Strides manufacture pharmaceutical formulations in various dosage forms, including capsules, tablets, liquid injectables and is one of the world's top five manufacturers of softgel capsules. Strides also have the only globally dedicated soft gel facility for hormones. In addition, Strides undertakes contract research and the manufacturing of specialty chemicals for various multinational companies. Strides have a major presence in various developing countries such as Africa, Latin America and Asia as well as in developed markets such as the US, Canada and part of Europe. Strides is one of the largest Indian suppliers of institutionally funded aid projects and is an approved supplier to the World Bank, the African Development Bank and UNICEF, amongst others.

Strides has 14 manufacturing plants spread across the Brazil, Mexico, Italy, Poland, Singapore and India. This broad manufacturing network facilities partnering with global organizations ranging from UNICEF and WHO-Global Drug Facility to European and American pharmaceutical multinationals and also private labelers and distribution chains. Strides has product registrations in over 37 countries around the world. The Indian manufacturing facilities for the regulated markets are approved by all major regulatory bodies such as MHRA, EU, TGA, MCC and USFDA and GMP accreditations including USFDA. Strides employ approximately 1,700 people across the globe. Strides also have a marketing presence in over 50 countries.

Additional information is available at the Company's website at www.stridesarco.com.

For further information, please contact:

Mr. Arun Kumar , Vice Chairman & Group CEO OR
Mr. Ravi Seth, CEO International Operations
Strides Arcolab Limited, Bangalore
Tel: +91 80 6658 0110, Fax: +91 80 6658 0200